"Yeah, the German accented Dr. was trying to equate/pump SGLT2's as a great Diabetes discovery that should be elevated and hailed as "on par" with the importance of the discovery of insulin.  I am not a Dr. but I don't get that sense, and its a stretch at best, at least from what I have learned about SGLT2's.....Bear, please correct me if I am wrong to resist's this Dr.s assertion."

SGLT2 inhibitors have shown some impressive effects on MACE reduction, kidney function and heart failure. In diabetic patients in particular, the ability of a diabetes drug to reduce MACE in addition to offering glucose lowering is extremely important due to the high residual MACE risk in these patients. The GLP1-R agonists are an important tool in the diabetes drug toolbox as well for this same reason. I don't have a link to the paper, but sounds like revised guidelines suggest SGLT2 inhibitors and GLP-1R agonists are now first line diabetes drugs (European guidelines?) according to this tweet I saw. These SGLT2 inhibitors and GLP-1R agonists have passed multiple Phase 3 trials in many thousands of patients, have been FDA approved and in real world use for many years now. They paid their dues and are getting the respect they deserve.

3-point MACE (especially cardio death), all cause mortality, renal function, heart failure, cognition.....these are just a subset of the things that apabetalone may improve in its diabetic BETonMACE patients. And these are the things that will capture the headlines. SGLT2 inhibitors and GLP1-R agonist are great, but there is still substantial remaining residual risk for cardiovascular, renal and other diseases. A perfect opportunity for apabetalone.

And importantly....as great as SGLT2 inhibitors and GLP-1R agonists are, these have never been proven effective in recent ACS diabetics. SGLT2 inhibitors have not been tested in this population and the GLP1-R agonist lixisenatide failed in the ELIXA trial (ACS within 180 days). Another diabetes drug, alogliptin, in the DPP4 inhibitor class failed in the EXAMINE trial in diabetics with ACS within 90 days. If BETonMACE succeeds, then this will be an unprecedented landmark finding, especially if the %RRR is through the roof with gravy of CKD and cognitive benefit.

BearDownAZ